SK Bioscience and VECOL Partner on Colombia Vaccine Manufacturing Initiative

Why It Matters

The agreement bolsters Colombia’s vaccine supply security while giving SK bioscience a strategic entry point into the Latin American market, accelerating regional self‑reliance in immunisation.

Key Takeaways

• SK bioscience partners with Colombia's VECOL for local vaccine production
• Initiative part of $260 million Colombian vaccine localisation plan
• SKYVaricella will be first product manufactured in Colombia
• SK gains preferential rights to supply Colombian government vaccines
• Partnership boosts Latin America vaccine self‑sufficiency after pandemic

Pulse Analysis

The Colombian government has launched a $260 million vaccine localisation programme aimed at reducing dependence on imports and strengthening public‑health resilience. After the COVID‑19 crisis revealed critical gaps in global supply chains, ministries and the state‑owned VECOL have been scouting partners that can meet WHO‑pre‑qualified standards. Over a four‑year evaluation, the authorities assessed technical expertise, regulatory compliance and long‑term collaboration potential, ultimately selecting a handful of firms to anchor the ten‑year self‑sufficiency drive.

SK bioscience, a South Korean leader in recombinant vaccines, signed a technology‑transfer and manufacturing pact with VECOL to produce its SKYVaricella varicella vaccine in Colombia. Under the agreement, SK will provide the know‑how for facility development, regulatory clearance and product rollout, while VECOL handles local operations, licensing and integration with the National Immunisation Programme. The deal grants SK preferential negotiation rights to supply its own and other vaccines to the Colombian government, creating a foothold for further portfolio expansion across the region.

The partnership signals a broader shift toward ‘glocalisation’ in the biotech sector, where multinational developers embed production within emerging markets to secure supply chains and tap growing demand. For Latin America, local manufacturing promises faster access to critical immunisations and a platform for regional export. SK’s move aligns with similar projects in Thailand and elsewhere, positioning the company as a key enabler of pandemic preparedness and sustainable vaccine availability throughout the continent.